Product Description
ISTH0036 is a 14-mer modified antisense oligodeoxynucleotide selectively targeting TGF-_2 mRNA. It exhibits potent activity in murine models of choroidal neovascularization (CNV). ISTH0036 induced a decrease in neovascularization, vascular leakage, fibrotic development, as well as blockage of epithelial-to-mesenchymal transition.Ê (Sourced from: https://iovs.arvojournals.org/article.aspx?articleid=2772908)
Mechanisms of Action: TGFb Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Isarna
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Macular Edema|Neovascular age-related macular degeneration
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2021-001213-36 |
Better | P2 |
Active, not recruiting |
Macular Edema|Neovascular age-related macular degeneration |
2022-08-24 |
2022-03-13 |
Treatments |